2023
Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
Flam-Ross J, Marsh E, Weitz M, Savinkina A, Schackman B, Wang J, Madushani R, Morgan J, Barocas J, Walley A, Chrysanthopoulou S, Linas B, Assoumou S. Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder. JAMA Network Open 2023, 6: e2329583. PMID: 37703018, PMCID: PMC10500382, DOI: 10.1001/jamanetworkopen.2023.29583.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineCost-Benefit AnalysisFemaleHumansMaleMiddle AgedOpioid-Related DisordersPatient Acceptance of Health CareUnited StatesConceptsExtended-release buprenorphineIncremental cost-effectiveness ratioMedication treatmentHealth care utilization costsTreatment of OUDOpioid agonist treatmentOpioid use disorderMean lifetime costsCost-effectiveness ratioProbabilistic sensitivity analysesEconomic evaluationCohort studyAgonist treatmentTreatment optionsClinical trialsClosed cohortMAIN OUTCOMEBuprenorphineSimulated cohortUse disordersDrug AdministrationUS FoodPharmaceutical costsQALY willingnessInjectable formEstimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics
Jawa R, Tin Y, Nall S, Calcaterra S, Savinkina A, Marks L, Kimmel S, Linas B, Barocas J. Estimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics. JAMA Network Open 2023, 6: e237888. PMID: 37043198, PMCID: PMC10098970, DOI: 10.1001/jamanetworkopen.2023.7888.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBuprenorphineCost-Benefit AnalysisHumansLife ExpectancyPrimary Health CareConceptsIncremental cost-effectiveness ratioPrimary care practitionersClinical outcomesPCP servicesPrimary careAddiction servicesAddiction careUS primary care clinicsLong-term clinical outcomesHealth care sector costsInjection-related infectionsPrimary care clinicsHealth care sector perspectivePrimary care practicesCost-effectiveness ratioObservational cohortBuprenorphine prescribingCare clinicsClinical trialsPCP practicesTreatment strategiesMAIN OUTCOMESimulated cohortCare practitionersCare practices
2022
Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study
Savinkina A, Bilinski A, Fitzpatrick M, Paltiel AD, Rizvi Z, Salomon J, Thornhill T, Gonsalves G. Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study. BMJ Open 2022, 12: e061752. PMID: 36100306, PMCID: PMC9471205, DOI: 10.1136/bmjopen-2022-061752.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisCOVID-19COVID-19 VaccinesDeveloping CountriesHumansMRNA VaccinesRNA, MessengerRNA, ViralSARS-CoV-2VaccinationVaccines, SyntheticConceptsLow-income countriesIncome countriesDeath avertedHigh-income nationsStatistical lifeAvertable deathsIncome nationsCOVID-19 deathsReasonable investmentHigh costKey inputCountriesParameter estimatesAvertedCostSensitivity analysisUniversal vaccinationGlobal vaccinationMRNA COVID-19 vaccinationNationsInvestmentPrimary vaccine seriesLow vaccine effectivenessCOVID-19 vaccinationPublic dataPopulation‐level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost‐effectiveness analysis
Savinkina A, Madushani RWMA, Yazdi G, Wang J, Barocas JA, Morgan JR, Assoumou SA, Walley AY, Linas BP, Murphy SM. Population‐level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost‐effectiveness analysis. Addiction 2022, 117: 2450-2461. PMID: 35315162, PMCID: PMC9377514, DOI: 10.1111/add.15879.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBuprenorphineCost-Benefit AnalysisDrug OverdoseHumansInpatientsOpiate Substitution TreatmentOpioid-Related DisordersUnited StatesConceptsIncremental cost-effectiveness ratioOpioid use disorderStandard of careUse disordersFatal overdosesDetox patientsMOUD initiationWithdrawal programInitiation of medicationHealth care sector perspectiveRisk of overdoseFatal opioid overdosesCost-effectiveness ratioCost-effectiveness analysisOpioid useHealth care spendingOutpatient careDetox programsOpioid overdosesMOUDPatientsOverdosesPopulation-level impactDisorder populationHealth effectsModeling the cost‐effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs
Adams JW, Savinkina A, Fox A, Behrends CN, Madushani RWMA, Wang J, Chatterjee A, Walley AY, Barocas JA, Linas BP. Modeling the cost‐effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs. Addiction 2022, 117: 2635-2648. PMID: 35315148, PMCID: PMC9951221, DOI: 10.1111/add.15883.Peer-Reviewed Original ResearchConceptsSyringe services programFatal opioid overdosesBuprenorphine-naloxone treatmentOpioid use disorderTreatment initiationBuprenorphine treatmentOpioid overdosesFatal overdosesSSP clientsActive opioid useCommunity treatment providersObservational cohort studyNational surveillance dataCost-effectiveness analysisCohort studyIntervention scenariosOpioid useBuprenorphine programOUD treatmentStatus quo scenarioClinical trialsFatal overdoseMore QALYsUse disordersTreatment engagementSimulated Cost-effectiveness and Long-term Clinical Outcomes of Addiction Care and Antibiotic Therapy Strategies for Patients With Injection Drug Use–Associated Infective Endocarditis
Adams JW, Savinkina A, Hudspeth JC, Gai MJ, Jawa R, Marks LR, Linas BP, Hill A, Flood J, Kimmel S, Barocas JA. Simulated Cost-effectiveness and Long-term Clinical Outcomes of Addiction Care and Antibiotic Therapy Strategies for Patients With Injection Drug Use–Associated Infective Endocarditis. JAMA Network Open 2022, 5: e220541. PMID: 35226078, PMCID: PMC8886538, DOI: 10.1001/jamanetworkopen.2022.0541.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalgesics, OpioidAnti-Bacterial AgentsAnti-Infective AgentsCost-Benefit AnalysisEndocarditisEndocarditis, BacterialFemaleHumansMaleConceptsOutpatient parenteral antimicrobial therapyIncremental cost-effectiveness ratioOral antibiotic therapyInjection drug use-associated infective endocarditisUsual care strategyAntibiotic therapyOpioid drug useAntibiotic treatment strategiesAntibiotic strategiesCare servicesTreatment strategiesCare strategiesTreatment discontinuationClinical outcomesInfective endocarditisDrug use-associated infective endocarditisDrug useInpatient intravenous antibiotic therapyLong-term clinical outcomesHigher treatment completion rateIntravenous antibiotic therapyObservational cohort studyPercentage of patientsPostacute care facilityParenteral antimicrobial therapy
2021
Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study
Barocas JA, Savinkina A, Adams J, Jawa R, Weinstein ZM, Samet JH, Linas BP. Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study. The Lancet Public Health 2021, 7: e56-e64. PMID: 34861189, PMCID: PMC8756295, DOI: 10.1016/s2468-2667(21)00248-6.Peer-Reviewed Original ResearchConceptsOpioid use disorderAddiction consult serviceHospital-based strategiesUS opioid epidemicOpioid epidemicUse disordersConsult serviceProbabilistic sensitivity analysesClinical impactDrug useIncremental cost-effectiveness ratioInjection-related infectionsInjection drug useMean lifetime costsNational InstituteCost-effectiveness ratioHarm reduction servicesDeterministic sensitivity analysesInpatient prescribingObservational cohortRecurrent infectionsOutpatient treatmentClinical trialsOverdose riskMedications